资金逆势流入港股创新药精选ETF(520690)，有机构认为港股创新药当前估值仍具吸引力

格隆汇2025-08-04

今年以来持续领涨的港股创新药近期迎来调整，资金借道ETF逆势加仓，港股创新药精选ETF(520690)在上周五资金净流入1689万元。港股创新药精选ETF(520690)紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。恒生港股通创新药精选指数年内...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2556871827?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-08-04 10:05","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2556871827","market":"sh","top_or_hot":-1,"title":"资金逆势流入港股创新药精选ETF(520690)，有机构认为港股创新药当前估值仍具吸引力","media":"格隆汇","content":"<div>\n<p>今年以来持续领涨的港股创新药近期迎来调整，资金借道ETF逆势加仓，港股创新药精选ETF(520690)在上周五资金净流入1689万元。\n港股创新药精选ETF(520690)紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n恒生港股通创新药精选指数年内...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n","source":"live_gelonghui","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>资金逆势流入港股创新药精选ETF(520690)，有机构认为港股创新药当前估值仍具吸引力</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n资金逆势流入港股创新药精选ETF(520690)，有机构认为港股创新药当前估值仍具吸引力\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-08-04 10:05 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/rss/live/live.xml><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>今年以来持续领涨的港股创新药近期迎来调整，资金借道ETF逆势加仓，港股创新药精选ETF(520690)在上周五资金净流入1689万元。\n港股创新药精选ETF(520690)紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n恒生港股通创新药精选指数年内...</p>\n\n<a href=\"https://www.gelonghui.com/rss/live/live.xml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"07226","symbol_name":"南方两倍做多恒科","start_time":0,"source_url":"https://www.gelonghui.com/rss/live/live.xml","article_id":"2556871827","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2556871827","pubTimestamp":1754273158,"columns":[],"sourceInfo":{"source_id":"live_gelonghui","name":"格隆汇"},"weMediaInfo":null,"summary":"今年以来持续领涨的港股创新药近期迎来调整，资金借道ETF逆势加仓，港股创新药精选ETF(520690)在上周五资金净流入1689万元。\n港股创新药精选ETF(520690)紧密跟踪恒生港股通创新药精选","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","603259":"药明康德","688235":"百济神州","07226":"南方两倍做多恒科","LU0456842615.SGD":"JPMorgan Funds - Emerging Markets Equity A (acc) SGD","01093":"石药集团","HSTECH":"恒生科技指数","LU2045819591.USD":"Natixis WCM Global Emerging Markets Equity R/A USD","LU0320764599.SGD":"FTIF - Templeton China A Acc SGD","ONC":"百济神州","01801":"信达生物","IE00B0JY6N72.USD":"PINEBRIDGE GLOBAL EMERGING MARKETS FOCUS EQUITY \"A\" (USD) ACC","02359":"药明康德","02269":"药明生物","BK4139":"生物科技","03692":"翰森制药","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","BK4614":"Manus概念股","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","BK4550":"红杉资本持仓","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","06160":"百济神州","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","BK1574":"生物医药B类股","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","FDN":"First Trust Dow Jones Internet I","LU0140636845.USD":"施罗德大中华区股票A Acc","01530":"三生制药","06978":"永泰生物-B","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","09926":"康方生物","BK1588":"回港中概股","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU0417516738.SGD":"Allianz Hong Kong Equity AT Acc SGD","LU1242518931.SGD":"Fullerton Lux Funds - Asia Absolute Alpha A Acc SGD","03329":"交银国际","BK4531":"中概回港概念","LU0516422366.SGD":"Fullerton Lux Funds - Asia Focus Equities A Acc SGD","LU1997245177.USD":"安联神洲A股基金","LU0979878070.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"A\" (USD) ACC","01177":"中国生物制药","LU0819121731.USD":"HSBC GIF MANAGED SOLUTIONS ASIA FOCUSED GROWTH \"AC\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","ZLAB":"再鼎医药","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","HSCEI":"国企指数","09688":"再鼎医药","YANG":"三倍做空富时中国ETF-Direxion","LU0456827905.SGD":"JPMorgan Funds - China A (acc) SGD"},"translate_title":"Funds bucked the trend and flowed into the Hong Kong Innovative Drug Select ETF (520690). Some institutions believe that the current valuation of Hong Kong innovative drugs is still attractive","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1,"603259":1,"688235":1,"03329":1,"ONC":1,"YANG":1,"HSTECH":1,"02359":1,"02269":1,"01093":1,"07226":1,"06160":1,"01801":1,"03692":1,"HSCEI":1,"01530":1,"01177":1,"09926":1,"09688":1,"06978":1,"FDN":1,"ZLAB":1},"content_text":"今年以来持续领涨的港股创新药近期迎来调整，资金借道ETF逆势加仓，港股创新药精选ETF(520690)在上周五资金净流入1689万元。\n港股创新药精选ETF(520690)紧密跟踪恒生港股通创新药精选指数，聚焦创新药龙头、精选高流动重研发标的，权重股包括百济神州、信达生物、药明生物、康方生物、石药集团、中国生物制药、三生制药、翰森制药、再鼎医药、药明康德等龙头公司。\n恒生港股通创新药精选指数年内涨超94%，最新市盈率32倍，估值处于上市以来36.78%分位；最新市销率3.54倍。\n交银国际认为，本轮港股创新药行情核心驱动力是价值重估，当前估值仍具吸引力，原因在于：\n1.头部创新药企的前瞻12个月市销率与熊市以来的历史均值基本持平，虽略高于美股可比公司、但营收增长预期亦远高于后者；收入达峰时的市销率对于创新药企长期潜力更有指导意义，目前港股龙头在3倍左右，低于美股平均的4倍，个别公司仅有2倍左右；\n2.今年上半年内资持续通过港股通加仓，但外资在创新药中的仓位处于底部，后者可能偏好基本面扎实、性价比显著的标的。\n综上，看好创新药板块整体继续修复的机会。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2556871827","isCrawlerRequest":true}